Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-2018682 SCHEMBL29692360 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| Gsk-2018682 SCHEMBL29691995 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| Gsk-2018682 SCHEMBL401576 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL400014 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL400074 | 0.91 | S1PR1 (0.83) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2124526 | 0.91 | S1PR1 (0.83) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL401724 | 0.89 | S1PR1 (0.92) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL404160 | 0.88 | S1PR1 (0.78) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2125416 | 0.88 | S1PR1 (0.78) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL1398446 | 0.88 | S1PR1 (0.78) | S1PR1S1PR3S1PR5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545890-B2 | Compositions and methods for derivation of trophoblast stem cells | NORTH CAROLINA STATE UNIVERSITY (US) | 2026-02-10 | — | — | US | claimed |
| US-20250325501-A1 | A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA | UNIV OTTO VON GUERICKE MAGDEBURG (DE) | 2025-10-23 | — | — | US | claimed |
| US-20250144081-A1 | METHODS FOR REDUCING ALCOHOL, DRUG, AND FOOD INTAKE | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-08 | — | — | US | claimed |
| US-20250136932-A1 | COMPOSITIONS AND METHODS FOR CULTURING AND MAINTAINING TROPHOBLAST STEM CELLS | NORTH CAROLINA STATE UNIVERSITY | 2025-05-01 | — | — | US | claimed |
| WO-2025083549-A1 | METHODS AND COMBINATIONS OF INHIBITORS OF IL-23 PATHWAY AND MODULATORS OF S1P SIGNALING PATHWAY FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2025-04-24 | — | — | WO | claimed |
| EP-4499056-A1 | A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA | Otto-von-Guericke-Universität Magdeburg (DE) | 2025-02-05 | — | — | EP | claimed |
| US-20240192235-A1 | CERAMIDE AND SPINGOMYELIN IN NEUROLOGICAL DISORDERS | THE TRUSTEES OF INDIANA UNIVERSITY | 2024-06-13 | — | — | US | claimed |
| US-11998602-B2 | Methods for promoting myelination and for treating demyelinating diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-06-04 | — | — | US | claimed |
| WO-2023187091-A1 | A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA | OTTO-VON-GUERICKE-UNIVERSITÄT MAGDEBURG (DE) | 2023-10-05 | — | — | WO | claimed |
| EP-4252748-A1 | A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA | Otto-von-Guericke-University Magdeburg (DE) | 2023-10-04 | — | — | EP | claimed |
| US-20220275330-A1 | COMPOSITIONS AND METHODS FOR DERIVATION OF TROPHOBLAST STEM CELLS | NORTH CAROLINA STATE UNIVERSITY | 2022-09-01 | — | — | US | claimed |
| US-20220213210-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | MABION SA (PL) | 2022-07-07 | — | — | US | claimed |
| WO-2022105220-A1 | NEW USE OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR IN PREPARATION OF MEDICAMENT FOR TREATING DIABETES | 睿阜隆(杭州)生物医药有限公司 | 2022-05-27 | — | — | WO | claimed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | claimed |
| EP-2206710-B1 | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2012-07-04 | — | — | EP | claimed |
| US-8101775-B2 | Indole derivatives as S1P1 Receptor | GLAXO GROUP LIMITED (GB) | 2012-01-24 | — | — | US | claimed |
| EP-2206710-A1 | Indole derivatives as S1P1 receptor agonists | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | claimed |
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | claimed |
| EP-2091949-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | claimed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR5 4/4885 |
| US-12545890-B2 | Compositions and methods for derivation of trophoblast stem cells | BMPR2, S1PR2, S1PR3 | S1PR1 6/4885S1PR3 3/4885S1PR5 7/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 5/4885S1PR5 4/4885 |
| US-20250144081-A1 | METHODS FOR REDUCING ALCOHOL, DRUG, AND FOOD INTAKE | LIPC, PNLIP, LPL | S1PR1 7/4885S1PR3 13/4885S1PR5 8/4885 |
| US-20220213210-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | CD209, MSR1, SIGLEC7 | S1PR1 57/4885S1PR3 65/4885S1PR5 60/4885 |
| US-20250325501-A1 | A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA | S1PR1, S1PR5, S1PR4 | S1PR1 1/4885S1PR3 5/4885S1PR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.